News & Updates
Filter by Specialty:
UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
In the treatment and prevention of recurrent yeast infection or vulvovaginal candidiasis, oteseconazole performs similarly to standard-of-care fluconazole but better as compared with placebo, as shown in the results of the phase III ultraviolet study.
UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
26 Jul 2022
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
Treatment with abrocitinib is both safe and effective in patients with moderate-to-severe atopic dermatitis (AD), regardless of prior dupilumab response status, a study has shown.
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
26 Jul 2022
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
26 Jul 2022
Biologic, thiopurine, methotrexate for IBD not detrimental to fertility
For male patients with inflammatory bowel disease (IBD), treatment with biologic, thiopurine, or methotrexate does not appear to promote impairments in fertility or adverse pregnancy outcomes, according to a study.
Biologic, thiopurine, methotrexate for IBD not detrimental to fertility
26 Jul 2022
Post-COVID-19 vax uveitis may be more common in Southeast Asia
COVID-19 vaccination-induced uveitis is uncommon, with cases mostly self-limiting and showing good responses to treatment with no long-term sequelae, according to a Singapore study. However, reactivation of such infections appears to occur at a higher proportion in Southeast Asia, where viral and toxoplasma infections are more common.
Post-COVID-19 vax uveitis may be more common in Southeast Asia
25 Jul 2022
Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication
Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.
Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication
25 Jul 2022
Secondary analysis boosts potential of atogepant for migraine prophylaxis in adults
In the secondary analysis of the phase III ADVANCE trial, responder rates were markedly higher with atogepant irrespective of dose than with placebo in adults with migraine.
Secondary analysis boosts potential of atogepant for migraine prophylaxis in adults
25 Jul 2022
SG: COPD severity a key factor when choosing between therapies
Chronic obstructive pulmonary disease (COPD) patients initiating treatment with a long-acting muscarinic antagonist (LAMA) plus a long-acting β2-agonist (LABA) tend to have higher disease severity than those who are started on LAMA, according to real-world data from Singapore. However, there are as many patients who experience clinical worsening in the LAMA group as there are in the LAMA+LABA group.